A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4
← catalyst calendarSponsored by Sarepta Therapeutics, Inc. (industry) · SRPT — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
17actual
Sites
10
Countries
Belgium, Germany, Italy +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-15 | actual | When the study began enrolling |
| Primary completion | 2025-03-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Limb-girdle Muscular Dystrophy
Interventions
- Biological: SRP-9003 — also filed as scAAVrh74.MHCK7.hSGCB, bidridistrogene xeboparvovec
- Drug: Glucocorticoid — also filed as Prednisone or equivalent
Primary outcome
what the primary-completion date above is the date OFCohort 1: Change from Baseline in β-SG Expression at Day 60 Post-dose as Measured by Immunofluorescence (IF) Percent β-SG Positive Fibers
measured Baseline, Day 60
Permalink · SRPT's whole pipeline · Catalyst calendar · Every registered study · What changed